Raymond James Financial
ORMP icon

Raymond James Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

Raymond James Financial’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,576
Closed -$8.05K – 6196
2025
Q2 		$8.05K Buy
+3,576
New +$7.89K ﹤0.01% 6013

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's ORMP Position: Q3 2025 in Review

Raymond James Financial sold out of Oramed Pharmaceuticals (ORMP) in Q3 2025, closing a stake of 3,576 shares — an estimated $8.05K sold.

Raymond James Financial first reported a position in ORMP in Q2 2025 and held it in 1 quarter. The position peaked at $8.05K in Q2 2025. 47 funds tracked by Wall St. Rank hold ORMP as of Q3 2025.

  • Raymond James Financial reported no remaining Oramed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 3,576 Oramed Pharmaceuticals shares in Q3 2025, an estimated $8.05K.
  • Raymond James Financial first reported a position in Oramed Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Oramed Pharmaceuticals position peaked at $8.05K in Q2 2025.
  • 47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.